Europe Cancer Treatment Market
市场规模（十亿美元）
CAGR :
% 
USD
115.67 Billion
USD
270.43 Billion
2025
2033
 Forecast Period |
2026 –2033 |
 Market Size (Base Year) |
USD 115.67 Billion |
 Market Size (Forecast Year) |
USD 270.43 Billion |
 CAGR |
% |
| Major Markets Players |
Europe Cancer Treatment Market, By Cancer Type (Breast Cancer, Colorectal Cancer with Liver Metastases, Lung Carcinoma, Prostate Cancer, Ovarian Cancer, Head-And-Neck Cancer, Pancreatic Cancer, Glioblastoma, Renal Cell Carcinoma, Anaplastic Thyroid Carcinoma, Sarcoma, and Others), Treatment (Medication, Targeted Therapies, Radiotherapy, Surgery, and Others), Route of Administration (Injectable, Oral, and Others), End User (Hospitals, Specialty Clinics), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Hungary, Netherlands, Switzerland, Lithuania, Austria, Norway, Ireland, Poland, and Rest of Europe) - Industry Trends and Forecast to 2029
Market Analysis and Insights: Europe Cancer Treatment Market
The Europe cancer treatment market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 11.2% in the forecast period of 2022 to 2029 and is expected to reach USD 172,492.46 million by 2029 from USD 75,654.50 million in 2021. The high prevalence of cancer and increasing R&D activities for its effective application are likely to be the major drivers that propel the market's demand in the forecast period.
Cancer is a disease in which some of the body's cells grow uncontrollably and eventually spread to other parts of the body. The cancerous tumor spreads to nearby tissues and can travel to distant places within the body to form a new tumor. This process is called metastases. The cancerous tumor is also referred to as a malignant tumor. The benign tumor does not invade nearby tissues, and when removed, benign tumors usually don't grow back, whereas cancerous tumors sometimes do.
There are more than a hundred types of cancer. Some categories of cancers that begin in specific types of cells include carcinoma, sarcoma, leukemia, lymphoma, and multiple myeloma, among others. Based on the type of cancer, many types of cancer treatments are available. The cancer treatment includes biomarker testing for cancer treatment, chemotherapy, hormone therapy, hyperthermia, immunotherapy, photodynamic therapy, radiation therapy, surgery, stem cell transplant, and targeted therapies, among others.
According to GLOBOCAN, 19,292,789 new cancer cases were found in 2020 worldwide. The highest cases of breast cancer were found. Therefore, the high prevalence of cancer, initiatives taken by the government for awareness and early detection of cancer, and ongoing clinical trials are expected to fuel the market's growth.
The high prevalence of cancer and rising government initiatives are expected to act as a driver for the growth of the market. However, the high cost of cancer treatment may restrain the market growth. The strategic initiatives taken by key market players are expected to act as an opportunity for the market's growth. However, the side effects of drugs may challenge the market's growth.
Europe cancer treatment market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Europe Cancer Treatment Market Scope and Market Size
The Europe cancer treatment market is categorized into four notable segments which are based on cancer type, treatment, route of administration, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of cancer type, the Europe cancer treatment market is segmented into breast cancer, colorectal cancer with liver metastases, lung carcinoma, prostate cancer, ovarian cancer, head-and-neck cancer, pancreatic cancer, glioblastoma, renal cell carcinoma, anaplastic thyroid carcinoma, and sarcoma. In 2022, the breast cancer segment is expected to dominate the market because of the launch of various awareness campaigns for the early detection and treatment of breast cancer.
- On the basis of treatment, the Europe cancer treatment market is segmented into medication, targeted therapies, radiotherapy, surgery, and others. In 2022, the medication segment is expected to dominate the market because of the launch of various types of drugs for treating cancer.
- On the basis of route of administration, the Europe cancer treatment market is segmented into injectable, oral, and others. In 2022, the injectable segment is expected to dominate the market because most of the cancer can be treated in injectable form.
- On the basis of end user, the Europe cancer treatment market is segmented into hospitals and specialty clinics. In 2022, the hospitals segment is expected to dominate the market due to advanced technology for cancer treatment available in the market.
Europe Cancer Treatment Market Country Level Analysis
The Europe cancer treatment market is analyzed, and market size information is provided by geography, cancer type, treatment, route of administration, and end user.
Some of the countries covered in the Europe cancer treatment market report are Germany, France, the U.K., Italy, Spain, Russia, Turkey, Belgium, Hungary, Netherlands, Switzerland, Lithuania, Austria, Norway, Ireland, Poland, and the Rest of Europe.
Europe is expected to grow with a CAGR of 11.2% in the forecasted period as in the European countries. The prevalence of cancer is high, and people are getting more aware of early diagnosis. Increasing healthcare infrastructure is expected to drive the growth of the Europe cancer treatment market. Germany is expected to dominate the European market due to the rise in approval of cancer drugs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in the Europe Cancer Treatment Market
The Europe cancer treatment market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the cancer treatment market. The data is available for the historical period 2011 to 2020.
Competitive Landscape and Europe Cancer Treatment Market Share Analysis
The Europe cancer treatment market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to the Europe cancer treatment market.
Some of the major companies providing the Europe cancer treatment market are Bristol-Myers Squibb Company, F. Hoffman La-Roche Ltd., Clegen, AbbVie, Inc., Pfizer, Inc., and Novartis AG, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The strategic initiatives by market players and new technological advancements for cancer treatment are bridging the gap for various treatments.
For instance,
- In January 2020, Novartis AG declared the acquisition with the Medicines Company. This acquisition has provided a novel opportunity to escalate its geographical presence across the world. As well as it has helped in upgrading the product portfolio of the company
Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the cancer treatment market, which also benefits the organization to improve their offering for the Europe cancer treatment market.
SKU-
目录
1 引言
1.1 研究目標
1.2 市場定義
1.3 歐洲、歐洲、澳洲、美國癌症治療市場概覽
1.4 限制
1.5 覆蓋市場
2 市場區隔
2.1 覆蓋市場
2.2 地理範圍
研究需時 2.3 年
2.4 貨幣和定價
2.5 DBMR三腳架資料驗證模型
2.6 多變量建模
2.7 癌症類型生命線曲線
2.8 與關鍵意見領袖的初步訪談
2.9 供應商份額分析
2.1 第二手資料
2.11 假設
3 執行摘要
4 項優質見解
4.1 佩爾斯特分析
4.2 波特五力模型
5 流行病學
6 歐洲癌症治療市場：監管情景
6.1 藥品核准時間表
7 市場概覽
7.1 驅動程式
7.1.1 全球癌症負擔不斷增加
7.1.2 老年人口不斷成長
7.1.3 不同類型標靶治療的可用性
7.1.4 FDA 核准數量不斷增加
7.1.5 不斷成長的研發活動
7.2 限制
7.2.1 與癌症治療藥物相關的不良反應和風險
7.2.2 癌症治療費用高昂
7.2.3 缺乏早期檢測
7.3 機遇
7.3.1 主要參與者之間的策略發展
7.3.2 政府和其他醫療機構的積極性不斷提高
7.3.3 癌症治療支出上升
7.4 挑戰
7.4.1 藥品專利到期
8 歐洲癌症治療市場（按癌症類型）
8.1 概述
8.2 乳癌
8.3 大腸直腸癌肝轉移
8.4 肺癌
8.5 攝護腺癌
8.6 卵巢癌
8.7 頭頸癌
8.8 胰臟癌
8.9 膠質母細胞瘤
8.1 腎細胞癌
8.11 甲狀腺未分化癌
8.12 肉瘤
9 歐洲癌症治療市場（依治療方法）
9.1 概述
9.2 藥物治療
9.2.1 依藥物類型
9.2.1.1 肺癌
9.2.1.1.1 納武單抗（Opdivo）
9.2.1.1.2 貝伐單抗（阿瓦斯汀）
9.2.1.1.3 克唑替尼（Xalkori）
9.2.1.1.4 厄洛替尼（特羅凱）
9.2.1.1.5 吉非替尼（易瑞沙）
9.2.1.1.6 馬來酸阿法替尼（阿法替尼）
9.2.1.1.7 色瑞替尼 (Ldk378/Zykadia)
9.2.1.1.8 雷莫蘆單抗（Cyramza）
9.2.1.1.9 其他
9.2.1.2 大腸直腸癌肝轉移
9.2.1.2.1 納武單抗（Opdivo）
9.2.1.2.2 西妥昔單抗（愛必妥）
9.2.1.2.3 帕尼單抗（Vectibix）
9.2.1.2.4 貝伐單抗（阿瓦斯汀）
9.2.1.2.5 Ziv-阿柏西普（Zaltrap）
9.2.1.2.6 瑞戈非尼（Stivarga）
9.2.1.2.7 雷莫蘆單抗（Cyramza）
9.2.1.2.8 伊匹單抗（Yervoy）
9.2.1.2.9 恩科拉非尼 (Braftovi)
9.2.1.2.10 帕博利珠單抗（Keytruda）
9.2.1.2.11 其他
9.2.1.3 卵巢癌
9.2.1.3.1 貝伐單抗（阿瓦斯汀）
9.2.1.3.2 奧拉帕尼（Lynparza）
9.2.1.3.3 魯卡帕尼樟磺酸鹽（Rubraca）
9.2.1.3.4 尼拉帕尼甲苯磺酸鹽一水合物（Zejula）
9.2.1.3.5 其他
9.2.1.4 頭頸癌
9.2.1.4.1 西妥昔單抗（愛必妥）
9.2.1.4.2 帕博利珠單抗（Keytruda）
9.2.1.4.3 納武單抗（Opdivo）
9.2.1.4.4 其他
9.2.1.5 腎細胞癌
9.2.1.5.1 納武單抗（Opdivo）
9.2.1.5.2 貝伐單抗（阿瓦斯汀）
9.2.1.5.3 索拉非尼（Nexavar）
9.2.1.5.4 舒尼替尼（Sutent）
9.2.1.5.5 帕唑帕尼（Votrient）
9.2.1.5.6 替西羅莫司（Torisel）
9.2.1.5.7 依維莫司 (Afinitor)
9.2.1.5.8 阿昔替尼（Inlyta）
9.2.1.5.9 卡博替尼（Cabometyx）
9.2.1.5.10 其他
9.2.1.6 未分化甲狀腺癌
9.2.1.6.1 卡博替尼 (Cometriq)
9.2.1.6.2 凡德他尼 (Caprelsa)
9.2.1.6.3 索拉非尼（Nexavar）
9.2.1.6.4 甲磺酸崙伐替尼（Lenvima）
9.2.1.6.5 曲美替尼 (Mekinist)
9.2.1.6.6 達拉非尼（Tafinlar）
9.2.1.6.7 賽帕替尼（Retevmo）
9.2.1.6.8 普拉替尼（加夫雷托）
9.2.1.6.9 其他
9.2.1.7 乳癌
9.2.1.7.1 依維莫司 (Afinitor)
9.2.1.7.2 他莫昔芬（諾瓦得士）
9.2.1.7.3 曲妥珠單抗（赫賽汀）
9.2.1.7.4 氟維司群（Faslodex）
9.2.1.7.5 阿那曲唑（Arimidex）
9.2.1.7.6 依西美坦（阿那曲唑）
9.2.1.7.7 來曲唑（Femara）
9.2.1.7.8 帕妥珠單抗（Perjeta）
9.2.1.7.9 哌柏西利（愛博新）
9.2.1.7.10 Ribociclib（Kisqali）
9.2.1.7.11 甲磺酸鹽（Talzenna）
9.2.1.7.12 帕博利珠單抗（Keytruda）
9.2.1.7.13 Margetuximab-Cmkb（Margenza）
9.2.1.7.14 其他
9.2.1.8 攝護腺癌
9.2.1.8.1 卡巴他賽（Jevtana）
9.2.1.8.2 恩雜魯胺 (Xtandi)
9.2.1.8.3 醋酸阿比特龍（Zytiga）
9.2.1.8.4 二氯化鐳223（Xofigo）
9.2.1.8.5 阿帕魯胺（Erleada）
9.2.1.8.6 達洛他胺（Nubeqa）
9.2.1.8.7 魯卡帕尼樟磺酸鹽（Rubraca）
9.2.1.8.8 奧拉帕尼（Lynparza）
9.2.1.8.9 其他
9.2.1.9 胰臟癌
9.2.1.9.1 厄洛替尼（特羅凱）
9.2.1.9.2 依維莫司 (Afinitor)
9.2.1.9.3 舒尼替尼（Sutent）
9.2.1.9.4 奧拉帕尼（Lynparza）
9.2.1.9.5 貝爾祖提凡 (Welireg)
9.2.1.9.6 其他
9.2.1.10 膠質母細胞瘤
9.2.1.10.1 貝伐單抗（阿瓦斯汀）
9.2.1.10.2 依維莫司 (Afinitor)
9.2.1.10.3 Belzutifan (Welireg)
9.2.1.10.4 其他
9.2.1.11 肉瘤
9.2.1.11.1 Cosmegen（放線菌素）
9.2.1.11.2 放線菌素
9.2.1.11.3 鹽酸阿黴素
9.2.1.11.4 甲磺酸艾日布林
9.2.1.11.5 格列衛（甲磺酸伊馬替尼）
9.2.1.11.6 Halaven（甲磺酸艾日布林）
9.2.1.11.7 甲磺酸伊馬替尼
9.2.1.11.8 鹽酸帕唑帕尼
9.2.1.11.9 他澤美司他氫溴酸鹽
9.2.1.11.10 Tazverik（氫溴酸他澤美司他）
9.2.1.11.11 曲貝替定
9.2.1.11.12 Votrient（鹽酸帕唑帕尼）
9.2.1.11.13 永德利斯（曲貝替定）
9.2.1.11.14 其他
9.2.2 通過疫苗
9.2.2.1 希瑞適
9.2.2.2 加德西
9.2.2.3 加德西-9
9.2.2.4 乙肝（Hbv）疫苗（Heplisav-B）
9.2.2.5 Sipuleucel-T（Provenge）
9.2.2.6 其他
9.3 放射治療
9.3.1 外照射放射治療
9.3.1.1 三維適形放射治療（3-D CRT）
9.3.1.2 質子治療
9.3.1.3 調強放射治療 (IMRT)
9.3.1.4 影像導引放射治療（IGRT）
9.3.1.5 斷層治療
9.3.1.6 立體定位放射外科
9.3.1.7 立體定位放射治療（SRT）
9.3.1.8 術中放射治療
9.3.1.9 其他
9.3.2 內放射治療（近距離放射治療）
9.3.2.1 低劑量率（LDR）近距離放射治療
9.3.2.2 高劑量率（HDR）近距離放射治療
9.3.3 全身放射治療
9.3.3.1 勝肽受體放射性核種治療（PRRT）
9.3.3.2 其他
9.4 手術
9.4.1 腮腺切除術
9.4.2 內視鏡手術
9.4.3 頸部清掃術
9.4.4 重建手術
9.4.5 其他
9.5 標靶治療
9.5.1 小分子
9.5.1.1 酪胺酸和絲胺酸/蘇胺酸激酶
9.5.1.1.1 伊馬替尼（格列衛）
9.5.1.1.2 吉非替尼（易瑞沙）
9.5.1.1.3 厄洛替尼（特羅凱）
9.5.1.1.4 舒尼替尼（索坦）
9.5.1.1.5 哌利福星
9.5.1.1.6 其他
9.5.1.2 蛋白酶體
9.5.1.2.1 硼替佐米（萬珂）
9.5.1.2.2 卡非佐米（Kyprolis）
9.5.1.2.3 馬里佐米
9.5.1.3 MMPS 和 HSPS
9.5.1.3.1 巴馬司他
9.5.1.3.2 新伐他汀
9.5.1.3.3 普利諾司他
9.5.1.3.4 瑞比馬司他
9.5.1.3.5 加奈特斯皮布
9.5.1.3.6 其他
9.5.1.4 細胞凋亡
9.5.1.4.1 奧巴克拉
9.5.1.4.2 納維托克
9.5.1.4.3 其他
9.5.2 免疫治療
9.5.2.1 免疫檢查點抑制劑
9.5.2.2 T細胞轉移療法
9.5.2.2.1 TIL治療
9.5.2.2.2 CAR-T細胞療法
9.5.2.2.3 按產品
9.5.2.2.3.1 tisagenlecleucel（kymriah）
9.5.2.2.3.2 axicabtagene ciloleucel（yescarta）
9.5.2.2.3.3 brexucabtagene autoleucel (tecartus)
9.5.2.2.3.4 其他
9.5.2.2.4 按技術
9.5.2.2.4.1 自體
9.5.2.2.4.2 同種異體
9.5.2.3 單株抗體
9.5.2.3.1 利妥昔單抗
9.5.2.3.2 博利妥單抗（blincyto）
9.5.2.3.3 其他
9.5.2.4 免疫系統調節劑
9.5.2.4.1 細胞因子
9.5.2.4.2 幹擾素（INFS）
9.5.2.4.3 白細胞介素（ILS）
9.5.2.4.4 造血生長因子
9.5.2.4.5 卡介苗
9.5.2.4.6 免疫調節藥物/生物反應調節劑
9.5.2.4.7 沙利度胺（沙利度胺）
9.5.2.4.8 來那度胺（來那度胺）
9.5.2.4.9 泊馬度胺（pomalyst）
9.5.2.4.10 咪喹莫特（aldara、zyclara）
9.5.2.4.11 其他
9.5.2.5 治療疫苗
9.5.2.6 其他
9.5.3 荷爾蒙治療
9.5.3.1 訊號傳導抑制劑
9.5.3.2 基因表現調節劑
9.5.3.3 凋亡誘導劑
9.5.3.4 血管新生抑制劑
9.5.3.5 基因治療
9.5.3.6 其他
9.6 其他
10 歐洲癌症治療市場（依給藥途徑）
10.1 概述
10.2 注射劑
10.3 口頭
10.4 其他
11 歐洲癌症治療市場（依最終使用者）
11.1 概述
11.2 醫院
11.3 專科診所
12. 歐洲癌症治療市場（按地區）
12.1 歐洲
12.1.1 德國
12.1.2 法國
12.1.3 英國
12.1.4 義大利
12.1.5 西班牙
12.1.6 荷蘭
12.1.7 丹麥
12.1.8 瑞士
12.1.9 瑞典
12.1.10 奧地利
12.1.11 挪威
12.1.12 匈牙利
12.1.13 希臘
14.12.1 愛爾蘭
15.12.1 波蘭
12.1.16 歐洲其他地區
13 歐洲癌症治療市場：公司格局
13.1 公司份額分析：歐洲
14 問卷
15份相關報告
表格列表
TABLE 1 DIFFERENCES IN APPROVAL TIMES BETWEEN EMEA AND FDA FOR SELECTED TARGETED THERAPIES SINCE 2001
TABLE 2 NEW CANCER CASES, AGES 85+ IN THE U.S.
TABLE 3 DEATH CAUSES DUE TO CANCER, AGES 85+ IN THE U.S.
TABLE 4 HERE ARE SOME STATISTICS RELATED TO THE TREATMENT COST:
TABLE 5 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 6 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 18 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 EUROPE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 24 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 25 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 27 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 28 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 29 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 30 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 31 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 32 EUROPE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 35 EUROPE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 36 EUROPE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 37 EUROPE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 38 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 40 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 42 EUROPE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 43 EUROPE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 45 EUROPE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 46 EUROPE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 47 EUROPE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 48 EUROPE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 49 EUROPE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 50 EUROPE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 51 EUROPE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 52 EUROPE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 EUROPE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 54 EUROPE OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 55 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 56 EUROPE INJECTABLE IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 57 EUROPE ORAL IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 58 EUROPE OTHERS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 59 EUROPE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 60 EUROPE HOSPITALS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 61 EUROPE SPECIALTY CLINICS IN CANCER TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 62 EUROPE CANCER TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 63 EUROPE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 64 EUROPE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 EUROPE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 66 EUROPE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 67 EUROPE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 68 EUROPE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 69 EUROPE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 70 EUROPE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 71 EUROPE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 72 EUROPE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 73 EUROPE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 74 EUROPE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 75 EUROPE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 76 EUROPE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 EUROPE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 78 EUROPE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 79 EUROPE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 80 EUROPE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 81 EUROPE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 82 EUROPE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 83 EUROPE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 84 EUROPE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 85 EUROPE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 86 EUROPE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 87 EUROPE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 88 EUROPE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 89 EUROPE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 90 EUROPE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 91 EUROPE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 92 EUROPE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 93 EUROPE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 94 EUROPE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 95 EUROPE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 96 EUROPE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 97 EUROPE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 98 EUROPE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 99 GERMANY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 100 GERMANY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 GERMANY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 102 GERMANY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 103 GERMANY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 104 GERMANY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 105 GERMANY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 106 GERMANY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 107 GERMANY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 108 GERMANY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 109 GERMANY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 110 GERMANY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 111 GERMANY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 112 GERMANY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 113 GERMANY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 114 GERMANY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 115 GERMANY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 116 GERMANY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 117 GERMANY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 118 GERMANY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 119 GERMANY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 120 GERMANY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 121 GERMANY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 122 GERMANY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 123 GERMANY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 124 GERMANY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 GERMANY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 126 GERMANY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 127 GERMANY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 128 GERMANY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 129 GERMANY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 130 GERMANY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 131 GERMANY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 132 GERMANY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 133 GERMANY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 134 GERMANY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 135 FRANCE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 136 FRANCE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 137 FRANCE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 138 FRANCE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 139 FRANCE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 140 FRANCE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 141 FRANCE OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 142 FRANCE HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 143 FRANCE RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 144 FRANCE ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 145 FRANCE BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 146 FRANCE PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 147 FRANCE PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 148 FRANCE GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 FRANCE SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 150 FRANCE BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 151 FRANCE RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 152 FRANCE EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 153 FRANCE INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 154 FRANCE SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 155 FRANCE SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 156 FRANCE TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 157 FRANCE SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 158 FRANCE TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 159 FRANCE PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 160 FRANCE MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 FRANCE APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 162 FRANCE IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 163 FRANCE T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 164 FRANCE BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 165 FRANCE BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 166 FRANCE MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 167 FRANCE IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 168 FRANCE HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 169 FRANCE CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 170 FRANCE CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 171 U.K. CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 172 U.K. CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 173 U.K. MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 174 U.K. BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 175 U.K. LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 176 U.K. COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 177 U.K. OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 178 U.K. HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 179 U.K. RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 180 U.K. ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 181 U.K. BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 182 U.K. PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 183 U.K. PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 184 U.K. GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 185 U.K. SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 186 U.K. BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 187 U.K. RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 188 U.K. EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 189 U.K. INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 190 U.K. SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 191 U.K. SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 192 U.K. TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 193 U.K. SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 194 U.K. TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 195 U.K. PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 196 U.K. MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 197 U.K. APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 198 U.K. IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 199 U.K. T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 200 U.K. BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 201 U.K. BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 202 U.K. MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 203 U.K. IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 204 U.K. HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 205 U.K. CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 206 U.K. CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 207 ITALY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 208 ITALY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 209 ITALY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 210 ITALY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 211 ITALY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 212 ITALY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 213 ITALY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 214 ITALY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 215 ITALY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 216 ITALY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 217 ITALY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 218 ITALY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 219 ITALY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 220 ITALY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 221 ITALY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 222 ITALY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 223 ITALY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 224 ITALY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 225 ITALY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 226 ITALY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 227 ITALY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 228 ITALY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 229 ITALY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 230 ITALY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 231 ITALY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 232 ITALY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 233 ITALY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 234 ITALY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 235 ITALY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 236 ITALY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 237 ITALY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 238 ITALY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 239 ITALY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 240 ITALY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 241 ITALY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 242 ITALY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 243 SPAIN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 244 SPAIN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 245 SPAIN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 246 SPAIN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 247 SPAIN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 248 SPAIN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 249 SPAIN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 250 SPAIN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 251 SPAIN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 252 SPAIN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 253 SPAIN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 254 SPAIN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 255 SPAIN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 256 SPAIN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 257 SPAIN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 258 SPAIN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 259 SPAIN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 260 SPAIN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 261 SPAIN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 262 SPAIN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 263 SPAIN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 264 SPAIN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 265 SPAIN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 266 SPAIN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 267 SPAIN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 268 SPAIN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 269 SPAIN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 270 SPAIN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 271 SPAIN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 272 SPAIN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 273 SPAIN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 274 SPAIN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 275 SPAIN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 276 SPAIN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 277 SPAIN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 278 SPAIN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 279 NETHERLANDS CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 280 NETHERLANDS CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 281 NETHERLANDS MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 282 NETHERLANDS BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 283 NETHERLANDS LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 284 NETHERLANDS COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 285 NETHERLANDS OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 286 NETHERLANDS HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 287 NETHERLANDS RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 288 NETHERLANDS ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 289 NETHERLANDS BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 290 NETHERLANDS PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 291 NETHERLANDS PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 292 NETHERLANDS GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 293 NETHERLANDS SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 294 NETHERLANDS BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 295 NETHERLANDS RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 296 NETHERLANDS EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 297 NETHERLANDS INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 298 NETHERLANDS SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 299 NETHERLANDS SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 300 NETHERLANDS TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 301 NETHERLANDS SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 302 NETHERLANDS TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 303 NETHERLANDS PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 304 NETHERLANDS MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 305 NETHERLANDS APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 306 NETHERLANDS IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 307 NETHERLANDS T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 308 NETHERLANDS BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 309 NETHERLANDS BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 310 NETHERLANDS MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 311 NETHERLANDS IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 312 NETHERLANDS HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 313 NETHERLANDS CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 314 NETHERLANDS CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 315 DENMARK CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 316 DENMARK CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 317 DENMARK MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 318 DENMARK BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 319 DENMARK LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 320 DENMARK COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 321 DENMARK OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 322 DENMARK HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 323 DENMARK RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 324 DENMARK ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 325 DENMARK BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 326 DENMARK PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 327 DENMARK PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 328 DENMARK GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 329 DENMARK SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 330 DENMARK BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 331 DENMARK RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 332 DENMARK EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 333 DENMARK INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 334 DENMARK SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 335 DENMARK SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 336 DENMARK TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 337 DENMARK SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 338 DENMARK TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 339 DENMARK PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 340 DENMARK MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 341 DENMARK APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 342 DENMARK IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 343 DENMARK T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 344 DENMARK BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 345 DENMARK BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 346 DENMARK MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 347 DENMARK IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 348 DENMARK HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 349 DENMARK CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 350 DENMARK CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 351 SWITZERLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 352 SWITZERLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 353 SWITZERLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 354 SWITZERLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 355 SWITZERLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 356 SWITZERLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 357 SWITZERLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 358 SWITZERLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 359 SWITZERLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 360 SWITZERLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 361 SWITZERLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 362 SWITZERLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 363 SWITZERLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 364 SWITZERLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 365 SWITZERLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 366 SWITZERLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 367 SWITZERLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 368 SWITZERLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 369 SWITZERLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 370 SWITZERLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 371 SWITZERLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 372 SWITZERLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 373 SWITZERLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 374 SWITZERLAND TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 375 SWITZERLAND PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 376 SWITZERLAND MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 377 SWITZERLAND APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 378 SWITZERLAND IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 379 SWITZERLAND T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 380 SWITZERLAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 381 SWITZERLAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 382 SWITZERLAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 383 SWITZERLAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 384 SWITZERLAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 385 SWITZERLAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 386 SWITZERLAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 387 SWEDEN CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 388 SWEDEN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 389 SWEDEN MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 390 SWEDEN BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 391 SWEDEN LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 392 SWEDEN COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 393 SWEDEN OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 394 SWEDEN HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 395 SWEDEN RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 396 SWEDEN ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 397 SWEDEN BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 398 SWEDEN PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 399 SWEDEN PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 400 SWEDEN GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 401 SWEDEN SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 402 SWEDEN BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 403 SWEDEN RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 404 SWEDEN EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 405 SWEDEN INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 406 SWEDEN SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 407 SWEDEN SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 408 SWEDEN TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 409 SWEDEN SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 410 SWEDEN TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 411 SWEDEN PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 412 SWEDEN MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 413 SWEDEN APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 414 SWEDEN IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 415 SWEDEN T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 416 SWEDEN BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 417 SWEDEN BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 418 SWEDEN MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 419 SWEDEN IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 420 SWEDEN HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 421 SWEDEN CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 422 SWEDEN CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 423 AUSTRIA CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 424 AUSTRIA CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 425 AUSTRIA MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 426 AUSTRIA BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 427 AUSTRIA LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 428 AUSTRIA COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 429 AUSTRIA OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 430 AUSTRIA HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 431 AUSTRIA RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 432 AUSTRIA ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 433 AUSTRIA BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 434 AUSTRIA PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 435 AUSTRIA PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 436 AUSTRIA GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 437 AUSTRIA SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 438 AUSTRIA BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 439 AUSTRIA RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 440 AUSTRIA EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 441 AUSTRIA INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 443 AUSTRIA SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 444 AUSTRIA SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 445 AUSTRIA TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 446 AUSTRIA SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 447 AUSTRIA TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 448 AUSTRIA PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 449 AUSTRIA MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 450 AUSTRIA APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 451 AUSTRIA IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 452 AUSTRIA T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 453 AUSTRIA BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 454 AUSTRIA BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 455 AUSTRIA MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 456 AUSTRIA IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 457 AUSTRIA HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 458 AUSTRIA CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 459 AUSTRIA CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 460 NORWAY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 461 NORWAY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 462 NORWAY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 463 NORWAY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 464 NORWAY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 465 NORWAY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 466 NORWAY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 467 NORWAY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 468 NORWAY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 469 NORWAY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 470 NORWAY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 471 NORWAY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 472 NORWAY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 473 NORWAY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 474 NORWAY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 475 NORWAY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 476 NORWAY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 477 NORWAY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 478 NORWAY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 479 NORWAY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 480 NORWAY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 481 NORWAY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 482 NORWAY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 483 NORWAY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 484 NORWAY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 485 NORWAY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 486 NORWAY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 487 NORWAY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 488 NORWAY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 489 NORWAY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 490 NORWAY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 491 NORWAY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 492 NORWAY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 493 NORWAY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 494 NORWAY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 495 NORWAY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 496 HUNGARY CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 497 HUNGARY CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 498 HUNGARY MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 499 HUNGARY BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 500 HUNGARY LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 501 HUNGARY COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 502 HUNGARY OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 503 HUNGARY HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 504 HUNGARY RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 505 HUNGARY ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 506 HUNGARY BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 507 HUNGARY PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 508 HUNGARY PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 509 HUNGARY GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 510 HUNGARY SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 511 HUNGARY BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 512 HUNGARY RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 513 HUNGARY EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 514 HUNGARY INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 515 HUNGARY SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 516 HUNGARY SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 517 HUNGARY TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 518 HUNGARY SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 519 HUNGARY TYROSINE & SERINE/THREONINE KINASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 520 HUNGARY PROTEOSOMES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 521 HUNGARY MMPS AND HSPS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 522 HUNGARY APOPTOSIS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 523 HUNGARY IMMUNOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 524 HUNGARY T-CELL TRANSFER THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 525 HUNGARY BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 526 HUNGARY BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 527 HUNGARY MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 528 HUNGARY IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 529 HUNGARY HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 530 HUNGARY CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 531 HUNGARY CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 532 GREECE CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 533 GREECE CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 534 GREECE MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 535 GREECE BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 536 GREECE LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 537 GREECE COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
表538 希臘卵巢癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表539 希臘癌症治療市場的頭頸癌，依治療方法，2020-2029（百萬美元）
表540希臘癌症治療中的腎細胞癌市場，依治療方法，2020-2029（百萬美元）
表541 希臘癌症治療市場的間變性甲狀腺癌，依治療方法，2020-2029（百萬美元）
表542 希臘乳癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表543 希臘前列腺癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表544 希臘癌症治療市場中的胰臟癌，依治療方法，2020-2029（百萬美元）
表545 希臘癌症治療市場中的膠質母細胞瘤，依治療方法，2020-2029（百萬美元）
表546 希臘癌症治療中的肉瘤市場，依治療方法，2020-2029（百萬美元）
表547 希臘癌症治療市場疫苗（依治療方法），2020-2029（百萬美元）
表548希臘癌症治療中的放射治療市場，依治療方法，2020-2029（百萬美元）
表549 希臘癌症治療市場中的外束放射治療，依治療方法，2020-2029（百萬美元）
表550 希臘癌症治療市場中的內部放射治療（近距離放射治療），依治療方法，2020-2029（百萬美元）
表551 希臘癌症治療市場中的系統性放射治療，依治療方法，2020-2029（百萬美元）
表552 希臘癌症手術治療市場，依治療方法，2020-2029（百萬美元）
表553 希臘癌症治療市場中的標靶療法，依治療方法，2020-2029（百萬美元）
表554 希臘癌症治療市場中的小分子，依治療方法，2020-2029（百萬美元）
表555 希臘癌症治療市場中的酪胺酸和絲胺酸/蘇胺酸激酶，依治療方法，2020-2029（百萬美元）
表556 希臘癌症治療市場中的蛋白酶體，依治療方法，2020-2029（百萬美元）
表557 希臘癌症治療市場中的MMPS和HSPS，依治療方法，2020-2029（百萬美元）
表558希臘癌症治療市場的細胞凋亡，依治療方法，2020-2029（百萬美元）
表559 希臘癌症治療中的免疫療法市場，依治療方法，2020-2029（百萬美元）
表560希臘癌症治療市場中的T細胞轉移療法，依治療方法，2020-2029（百萬美元）
表561 希臘癌症治療市場產品分類（2020-2029）（百萬美元）
表562 希臘癌症治療市場技術分類，依治療方法，2020-2029（百萬美元）
表563 希臘癌症治療市場中的單株抗體，依治療方法，2020-2029（百萬美元）
表564 希臘免疫系統調節劑在癌症治療市場的應用，依治療方法，2020-2029（百萬美元）
表565 希臘癌症治療中的荷爾蒙療法市場，依治療方法，2020-2029（百萬美元）
表566 希臘癌症治療市場，依給藥途徑，2020-2029（百萬美元）
表567 希臘癌症治療市場，依最終用戶，2020-2029（百萬美元）
表 568 愛爾蘭癌症治療市場，依癌症類型，2020-2029（百萬美元）
表 569 愛爾蘭癌症治療市場，依治療方法，2020-2029（百萬美元）
表570 愛爾蘭癌症治療藥物市場，依治療方法，2020-2029（百萬美元）
表571 愛爾蘭癌症治療市場藥物類型（依治療方法劃分），2020-2029（百萬美元）
表572 愛爾蘭癌症治療中的肺癌市場，依治療方法，2020-2029（百萬美元）
表573 愛爾蘭癌症治療市場中大腸直腸癌伴隨肝轉移的治療，依治療方法，2020-2029（百萬美元）
表574 愛爾蘭卵巢癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表575 愛爾蘭頭頸癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表576 愛爾蘭癌症治療中的腎細胞癌市場，依治療方法，2020-2029（百萬美元）
表577 愛爾蘭癌症治療市場的間變性甲狀腺癌，依治療方法，2020-2029（百萬美元）
表578 愛爾蘭乳癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表579 愛爾蘭攝護腺癌癌症治療市場，依治療方法，2020-2029（百萬美元）
表580 愛爾蘭癌症治療市場的胰臟癌，依治療方法，2020-2029（百萬美元）
表581 愛爾蘭膠質母細胞瘤癌症治療市場，依治療方法，2020-2029（百萬美元）
表582 愛爾蘭癌症肉瘤治療市場，依治療方法，2020-2029（百萬美元）
表583 愛爾蘭癌症治療市場疫苗（依治療方法），2020-2029（百萬美元）
表 584 愛爾蘭癌症治療中的放射治療市場，依治療方法，2020-2029（百萬美元）
表585 愛爾蘭癌症治療市場外束放射治療（依治療方法），2020-2029（百萬美元）
表586 愛爾蘭癌症治療市場中的內放射治療（近距離放射治療），依治療方法，2020-2029（百萬美元）
表587 愛爾蘭癌症治療市場中的全身放射治療，依治療方法，2020-2029（百萬美元）
表588 愛爾蘭癌症手術治療市場，依治療方法，2020-2029（百萬美元）
表589 愛爾蘭癌症治療市場中的標靶療法，依治療方法，2020-2029（百萬美元）
表590 愛爾蘭癌症治療市場中的小分子，依治療方法，2020-2029（百萬美元）
表591 愛爾蘭癌症治療市場中的酪胺酸和絲胺酸/蘇胺酸激酶，依治療方法，2020-2029（百萬美元）
表592 愛爾蘭癌症治療市場中的蛋白酶體，依治療方法，2020-2029（百萬美元）
表 593 愛爾蘭癌症治療市場中的 MMPS 和 HSPS，依治療方法，2020-2029（百萬美元）
表594 愛爾蘭癌症治療市場的細胞凋亡，依治療方法，2020-2029（百萬美元）
表 595 愛爾蘭癌症治療中的免疫療法市場，依治療方法，2020-2029（百萬美元）
表596 愛爾蘭T細胞轉移療法在癌症治療市場的應用，依治療方法，2020-2029（百萬美元）
TABLE 597 IRELAND BY PRODUCT IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 598 IRELAND BY TECHNOLOGY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 599 IRELAND MONOCLONAL ANTIBODIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 600 IRELAND IMMUNE SYSTEM MODULATORS IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 601 IRELAND HORMONAL THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 602 IRELAND CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 603 IRELAND CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 604 POLAND CANCER TREATMENT MARKET, BY CANCER TYPE, 2020-2029 (USD MILLION)
TABLE 605 POLAND CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 606 POLAND MEDICATION IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 607 POLAND BY DRUG TYPE IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 608 POLAND LUNG CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 609 POLAND COLORECTAL CANCER WITH LIVER METASTASES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 610 POLAND OVARIAN CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 611 POLAND HEAD-AND-NECK CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 612 POLAND RENAL CELL CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 613 POLAND ANAPLASTIC THYROID CARCINOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 614 POLAND BREAST CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 615 POLAND PROSTATE CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 616 POLAND PANCREATIC CANCER IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 617 POLAND GLIOBLASTOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 618 POLAND SARCOMA IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 619 POLAND BY VACCINES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 620 POLAND RADIOTHERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 621 POLAND EXTERNAL BEAM RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 622 POLAND INTERNAL RADIATION THERAPY (BRACHYTHERAPY) IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 623 POLAND SYSTEMIC RADIATION THERAPY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 624 POLAND SURGERY IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 625 POLAND TARGETED THERAPIES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 626 POLAND SMALL MOLECULES IN CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
表627波蘭癌症治療市場中的酪胺酸和絲胺酸/蘇胺酸激酶，依治療方法，2020-2029（百萬美元）
表628波蘭癌症治療市場中的蛋白酶體，依治療方法，2020-2029（百萬美元）
表 629 波蘭癌症治療市場中的 MMPS 和 HSPS，依治療方法，2020 至 2029 年（百萬美元）
表630波蘭癌症治療市場中的細胞凋亡，依治療方法，2020-2029（百萬美元）
表631波蘭癌症治療中的免疫療法市場，依治療方法，2020-2029（百萬美元）
表632波蘭癌症治療市場中的T細胞轉移療法，依治療方法，2020-2029（百萬美元）
表633 波蘭癌症治療市場產品分類（2020-2029）（百萬美元）
表634 波蘭癌症治療市場技術分析（2020-2029）（百萬美元）
表635波蘭癌症治療市場中的單株抗體，依治療方法，2020-2029（百萬美元）
表 636 波蘭免疫系統調節劑在癌症治療市場的應用，依治療方法，2020-2029（百萬美元）
表637波蘭癌症治療中的荷爾蒙療法市場，依治療方法，2020-2029（百萬美元）
表 638 波蘭癌症治療市場，依給藥途徑，2020-2029（百萬美元）
表 639 波蘭癌症治療市場，按最終用戶，2020 VS 2029（百萬美元）
表 640 歐洲其他地區癌症治療市場（以癌症類型），2020 VS 2029（百萬美元）
图片列表
圖 1 歐洲、歐洲、澳洲、美國癌症治療市場：細分
圖 2 歐洲、歐洲、澳洲、美國癌症治療市場：數據三角測量
圖 3 歐洲、歐洲、澳洲、美國癌症治療市場：DROC 分析
圖4 歐洲、歐洲、澳洲、美國癌症治療市場：歐洲與區域市場分析
圖5 歐洲、歐洲、澳洲、美國癌症治療市場：公司研究分析
圖 6 歐洲、歐洲、澳洲、美國癌症治療市場：訪談人口統計
圖 7 歐洲、歐洲、澳洲、美國癌症治療市場：供應商份額分析
圖 8 歐洲、歐洲、澳洲、美國癌症治療市場：細分
圖9 預計2022年至2029年預測期間癌症高發生率將推動歐洲、歐洲、澳洲、美國癌症治療市場的發展
圖 10 預計乳癌治療將在 2022 年至 2029 年佔據歐洲、歐洲、澳洲、美國癌症治療市場的最大份額
圖11 歐洲、歐洲、澳洲、美國癌症治療市場的驅動因素、限制因素、機會與挑戰
圖12 2020年全球各類癌症新發病例及死亡人數估計
圖 13 2018 年全球各年齡層男女新發病例估計數
圖 14 歐洲癌症治療市場：依癌症類型，2021 年
圖 15 歐洲癌症治療市場：按癌症類型，2020-2029 年（百萬美元）
圖 16 歐洲癌症治療市場：依癌症類型、複合年增長率（2022-2029）
圖 17 歐洲癌症治療市場：依癌症類型、生命線曲線
圖 18 歐洲癌症治療市場：依治療方法，2021 年
圖 19 歐洲癌症治療市場：依治療方法，2020-2029 年（百萬美元）
圖 20 歐洲癌症治療市場：依治療複合年增長率（2022-2029）
圖 21 歐洲癌症治療市場：依治療生命線曲線
圖 22 歐洲癌症治療市場：依給藥途徑，2021 年
圖 23 歐洲癌症治療市場：依給藥途徑，2020-2029 年（百萬美元）
圖 24 歐洲癌症治療市場：依給藥途徑、複合年增長率（2022-2029）
圖 25 歐洲癌症治療市場：依給藥途徑生命線曲線
圖 26 歐洲癌症治療市場：依最終使用者劃分，2021 年
圖 27 歐洲癌症治療市場：按最終用戶劃分，2020-2029 年（百萬美元）
圖 28 歐洲癌症治療市場：依最終使用者、複合年增長率（2022-2029）
圖 29 歐洲癌症治療市場：依最終用戶生命線曲線
圖 30 歐洲癌症治療市場：快照（2021 年）
圖 31 歐洲癌症治療市場：依國家（2021 年）
圖 32 歐洲癌症治療市場：依國家（2022 年和 2029 年）
圖 33 歐洲癌症治療市場：依國家（2021 年和 2029 年）
圖 34 歐洲癌症治療市場：依癌症類型（2022-2029）
圖35 歐洲癌症治療市場：2021年公司佔有率（％）
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
